Apremilast
DrugApremilast
Other names: Otezla
NCT Number: NCT03608657
This will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study, to initiate treatment with Otezla® will be considered for participation in the study.
Patients will be enrolled from the practices of predominantly community rheumatologists and will be followed for 12 months from the time of initiation of treatment with Otezla® In line with the observational nature of the study, there will be no protocol imposed tests or assessments. However, recommended follow up visits will be at 4, 8 and 12 months. In addition, patients may be asked to voluntarily complete self-administered questionnaires.
The 24-month assessment will be aimed to determine whether or not treatment with Otezla® has been maintained, and if not, to ascertain the reason for discontinuation and what new treatment was initiated following discontinuation of Otezla®
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
The Waterside Clinic, Barrie, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Apremilast
Other names: Otezla
Time frame: Up to approximately 1 year
Is defined as Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) < 14. cDAPSA is calculated as the sum of TJC - 68, SJC - 66, PtGA (10-cm VAS) and Pain (10-cm VAS).
Time frame: Up to approximately 8 months
Is defined as Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) < 14. cDAPSA is calculated as the sum of TJC - 68, SJC - 66, PtGA (10-cm VAS) and Pain (10-cm VAS).
Time frame: Up to Approximately 1 year
Based on 68/66 joints to determine joint pain/tenderness and joint swelling, as conducted during the physical examination and per the practices of the treating physician
Time frame: Up to Approximately 1 year
Based on 68/66 joints to determine joint pain/tenderness and joint swelling, as conducted during the physical examination and per the practices of the treating physician
Time frame: Up to Approximately 1 year
This is completed by the treating physician and assesses tenderness at six (6) sites, specifically two (2) lateral at the following: epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. The LEI is scored between 0 and 6. Resolution versus improvement versus no change versus worsening of enthesitis since the last available assessment
Time frame: Up to approximately 1 year
Resolution versus improvement versus no change versus worsening of dactylitis since the last available assessment
Time frame: Up to approximately 1 year
height (cm) x weight (kg)/3600)½
Time frame: Up to approximately 1 year
This is a self-administered questionnaire measuring the patient's functional ability during the last week. It consists of 20 items converging to 8 scales measuring dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The patients rate each activity as 0 = without any difficulty, 1 = some difficulty, 2 = much difficulty and 4 = unable. The final score ranges from 0 to 3 with higher scores indicating more disability.
Time frame: Up to approximately 1 year
This is a 100-mm visual analog scale (VAS) with 0 indicating lowest disease and 100 highest disease activities
Time frame: Up to approximately 1 year
This is a 100-mm VAS with 0 indicating lowest disease and 100 highest disease activity
Time frame: Up to approximately 1 year
This is a 14-item questionnaire evaluating patient satisfaction in terms of the following: effectiveness, side effects, convenience, and global satisfaction
Time frame: Up to approximately 1 year
Patient subjective assessment of Pain using a 100mm VAS
Time frame: Up to approximately 1 year
A 6-item questionnaire assessing the effect of PsA on the patient's ability to work and perform daily activities. It assesses presenteeism, absenteeism, productivity and activity impairment
Time frame: Up to approximately 1 year
A generic quality of life index that is comprised of 36 items converging to eight (8) domains: Vitality, Physical Functioning, Bodily Pain, General Health Perception, Physical Role Functioning, Emotional Role Functioning, Social Role Functioning, and Mental Health
Time frame: Up to approximately 1 year
An optional weekly take-home diary will be offered to patients; this diary will aid in documenting how many doses (if any) of PsA treatment were missed, and the reason(s) why.
Time frame: Up to approximately 1 year
A single question phrased as "If you were to remain for the next few months as you were during the last week, would this be acceptable or unacceptable to you?" with a binary (Yes or No) response
Time frame: From enrollment until at least 28 days after completion of study treatment
Number of subjects with adverse events
Amgen
Industry
Observational Study Evaluating the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
Acronym: APPRAISE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05071664
Arthritis, Arthritis, Psoriatic
Phoenix, Arizona, United States
View Trial DetailsNCT03158285
Arthritis, Arthritis, Psoriatic
Birmingham, Alabama, United States
View Trial DetailsNCT05571696
Arthritis, Arthritis, Psoriatic
Cleveland, Ohio, United States
View Trial DetailsNCT03106051
Arthritis, Arthritis, Psoriatic
Altona, Free and Hanseatic City of Hamburg, Germany
View Trial Details